Ionis Pharmaceuticals, Inc.
IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$75.36
Price+1.78%
$1.32
1Y
Price
Market Cap
$12.449b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+2269.7%
EBITDA Margin-112.8%
Net Profit Margin-78.3%
Free Cash Flow Margin+2269.7%
EBITDA Margin-112.8%
Net Profit Margin-78.3%
Free Cash Flow MarginRevenue
$944m
+33.8%
1y CAGR+19.1%
3y CAGR+7.5%
5y CAGREarnings
-$381m
+16.1%
1y CAGR-14.6%
3y CAGR-221.7%
5y CAGREPS
-$2.38
+19.1%
1y CAGR-11.5%
3y CAGR-221.1%
5y CAGRBook Value
$489.089m
$3.524b
Assets$3.035b
Liabilities$2.614b
DebtDebt to Assets
74.2%
0.6x
Debt to EBITDAFree Cash Flow
-$320.027m
+41.4%
1y CAGR-11.8%
3y CAGR-604.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company